CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 47 enrolled
Drug / intervention
V117957 +1 moredrug
Likely dose
V117957 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06285214
NCT06285214Phase 1Completed
CompareCT.gov

Multicenter, Randomized, Double-blind Placebo-controlled, Crossover Study to Investigate Effects of V117957 in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Imbrium Therapeutics·interventional·Posted Feb 29, 2024·Updated Mar 9, 2026

In Brief

A Phase 1 clinical trial evaluating V117957 and Placebo for Interstitial Cystitis/Bladder Pain Syndrome. Completed, enrolled 47 participants across 24 sites.

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInterstitial Cystitis/Bladder Pain Syndrome
CountriesUnited States
CollaboratorsPurdue Pharma LP

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedFeb 29, 2024
Enrollment StartMay 26, 2022
Primary CompletionJan 28, 2025
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 2.3 years ago

Interventions

V117957drug

V117957 1 mg - 1 tablet taken orally at bedtime.

Placebodrug

Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.